

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: August 7, 2006

ATTY DOCKET NO.  
2006\_1298ASERIAL NO.  
NEWAPPLICANT  
Takayuki HIDA et al.FILING DATE  
August 7, 2006

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/RL/	AJ	2004/112575 A2	12/2004	WO			
/RL/	AK	03/030930 A1	4/2003	WO			
	AL						
	AM						
	AN						

## OTHER DOCUMENT(S) (including Author, Title, Date, Pertinent Pages, Etc.)

/RL/	AO	C. Liu et al., Identification of relaxin-3/ INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135, 2003, J.Biol.Chem., 278(50), p.50754-64.
	AP	C. Liu et al., Identification of relaxin-3/ INSL7 as a ligand for GPCR142, 2003, J.Biol.Chem., 278(50), p. 50765-70.
	AQ	R.A. Bathgate et al., Relaxin: new peptides, receptors and novel actions, 2003, Trends Endocrinol Metab, 14(5), p. 207-13.
	AR	H. KIZAWA et al., Production of recombinant human relaxin 3 in AtT20 cells, 2003, Regul. Pept., 113(1-3), pages 79 to 84.
	AS	S. SUDO et al., H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2, 2003, J. Biol.Chem., 278(10), p. 7855-62.
	AT	C.S. Samuel et al., Physiological or pathological-a role for relaxin in the cardiovascular system?, 2003, Curr.Opin. Pharmacol., 3(2), p. 152-8.

EXAMINER

/Robert Landsman/

DATE CONSIDERED

10/02/2008